GSTP1 and lung adenocarcinoma: GSTP1 inhibitor Ezastiostat exhibits the potential as a combined treatment with tyrosine kinase inhibitor (TKI) to reverse TKI resistance, illustrating GSTP1 as promising therapeutic target for lung adenocarcinoma.